Group items tagged

Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, Arita M, Serhan CN. Chem Biol. 2006 Nov;13(11):1193-202. PMID: 17114001 doi:10.1016/j.chembiol.2006.09.011

Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. J Immunol. 2007 Mar 15;178(6):3912-7. PMID: 17339491

Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. Lu Y, Hong S, Yang R, Uddin J, Gotlinger KH, Petasis NA, Serhan CN. Rapid Commun Mass Spectrom. 2007;21(1):7-22. PMID: 17131464

Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Serhan CN, Gotlinger K, Hong S, Arita M. Prostaglandins Other Lipid Mediat. 2004 Apr;73(3-4):155-72. Review. PMID: 15290791

Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. J Exp Med. 2005 Mar 7;201(5):713-22. PMID: 15753205 oi:10.1084/jem.20042031

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.\nDemark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT.\nUrology. 2001 Jul;58(1):47-52.\nPMID: 11445478 \ndoi:10.1016/S0090-4295(01)01014-7  

Meat intake and bladder cancer risk in 2 prospective cohort studies.\nMichaud DS, Holick CN, Giovannucci E, Stampfer MJ.\nAm J Clin Nutr. 2006 Nov;84(5):1177-83.\nPMID: 17093172

"This website is about Vitamin D and MS Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), with an uncertain cause. Colleen Hayes and Donald Achaeson have suggested that insufficient sunlight exposure and chronic viral infections might be unrelated environmental risk factors for MS. These risk factors may act synergistically to enable the pathogenic autoimmune response. The prevalence of MS is highest where environmental supplies of vitamin D are lowest. Sunshine enables the production of vitamin D3 (VD3) in the skin. Epidemiological studies have shown that higher vitamin D blood levels are associated with lower risk, less relapses and a slower progression of multiple sclerosis. Higher vitamin D levels can be achieved in part by increased oral intake of VD3. Optimal health requires serum 25 hydroxyvitamin D levels higher than 20 ng/ml (50 nmol/L) P Lips, 40 ng/ml (100 nmol/L) P Heaney or at least 40 ng/ml (100 nmol/L) R Vieth. "

Infant vitamin d supplementation and allergic conditions in adulthood: northern Finland birth cohort 1966. Hyppönen E, Sovio U, Wjst M, Patel S, Pekkanen J, Hartikainen AL, Järvelinb MR. Ann N Y Acad Sci. 2004 Dec;1037:84-95. PMID: 15699498

Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Kulkami SK et al. Phytotherapy Research, Published Online: 8 Dec 2009 This review attempts to discuss the pharmacological basis of the use of berberine in various central nervous system and related disorders. Its protective effect in Alzheimer's, cerebral ischemia, mental depression, schizophrenia and anxiety are highlighted. However, more detailed clinical trials along with a safety assessment of berberine are warranted for positioning the alkaloid in the treatment of neurological disorders.

EMS is a technique to induce muscle contraction. Here impulses are generated by a device (Jointex) placed near the affected area, which mimic's the action potential coming from CNS causing the muscle to contract.